Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

C-Control: Efficacy and Safety of Therapy With Rosuvastatin in Statin-Naive and in Statin-Switched Patients

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: May 29, 2008
Last updated: April 8, 2009
Last verified: April 2009

The study explores efficacy and safety of the lipid-lowering therapy with CRESTOR in statin-naive patients and in patients with previously unsuccessful statin therapy. This study was designed to investigate the dynamic of the lipid parameters and therapy tolerability during 8-10 weeks treatment with CRESTOR


Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: C-Control: Efficacy and Safety of Therapy With Rosuvastatin in Statin-Naive and in Statin-Switched Patients

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • LDL-Cholesterin, HDL-Cholesterin, Triglycerides, Total Cholesterin [ Time Frame: 3 visits within 10 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Tolerability of CRESTOR-therapy [ Time Frame: 3 visits within 10 weeks ] [ Designated as safety issue: No ]

Enrollment: 3392
Study Start Date: February 2007
Study Completion Date: January 2008
Pt with hypercholesteremia
Patients treated with CRESTOR because of hypercholesteremia


Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Statin-naive patients and unsuccessfully treated with other (non rosubastatin) statins patients


Inclusion Criteria:

  • Patients with hypercholesteremia who was never treated with statins before
  • Patient with hypercholesteremia who was treated with a statin (other then rosuvastatin) but because of its adverse effects/insufficient action was switched to therapy with CRESTOR

Exclusion Criteria:

  • None
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

No publications provided

Responsible Party: Dr med Madeleine Billeter, AstraZeneca AG, Switzerland Identifier: NCT00688454     History of Changes
Other Study ID Numbers: NIS-CCH-CRE-2007/1
Study First Received: May 29, 2008
Last Updated: April 8, 2009
Health Authority: Switzerland: Ethikkommission

Keywords provided by AstraZeneca:
CRESTOR therapy

Additional relevant MeSH terms:
Lipid Metabolism Disorders
Metabolic Diseases
Anticholesteremic Agents
Enzyme Inhibitors
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypolipidemic Agents
Lipid Regulating Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses processed this record on November 20, 2014